Estudio aleatorizado, doble ciego y controlado con placebo de ALE.F02 administrado por vía intravenosa para evaluar la seguridad, la tolerabilidad, la farmacocinética y el efecto nefroprotector en pacientes con vasculitis asociada a ANCA

Description

Estudio clínico que evalúa un medicamento experimental, ALE.F02, administrado por vía intravenosa cada dos semanas durante 6 meses, en pacientes con vasculitis asociada a ANCA y daño renal rápidamente progresivo. Su objetivo es comprobar la seguridad y tolerabilidad del tratamiento, cómo lo procesa el organismo y si ayuda a proteger los riñones. Se compara con un placebo para valorar sus posibles beneficios y efectos adversos.

Financing

Alentis Therapeutics AG

Highlighted information

Publication date
Project code
ALE.F02.03
Diseases & conditions
Vasculitis ANCA
Principal Investigator
Juliana Bordignon
Contact email
jbordignon@bellvitgehospital.cat
Opened

Subscribe to our monthly newsletter, "Have a Healthy Life", with health information for everyone.

Acceptance of these terms implies your consent for the processing of your personal data to provide the services you request through this portal and, if necessary, to carry out the necessary arrangements with public administrations or entities involved in the process, and their subsequent incorporation into the mentioned automated file. You may exercise your rights of access, rectification, cancellation, and objection by writing to comunicacio@bellvitgehospital.cat, clearly stating "Exercise of LOPD rights" in the subject line.

Responsible: Hospital Universitari de Bellvitge.
Purpose: To manage user contact
Legal basis: Express acceptance of the privacy policy.
Rights: Access, rectification, deletion, and portability of data, limitation, and objection to its processing.
Source: The data subject.